saraf Antibody

What is SARAF and why are antibodies against it important for research?

SARAF (also known as TMEM66) functions as a negative regulator of store-operated calcium entry (SOCE), protecting cells from calcium overfilling. It responds to cytosolic Ca²⁺ elevation after endoplasmic reticulum Ca²⁺ refilling by promoting slow inactivation of STIM-dependent SOCE activity . SARAF facilitates the deoligomerization of STIM proteins to efficiently turn off ORAI channels when the endoplasmic reticulum contains appropriate Ca²⁺ levels, preventing cellular Ca²⁺ overload.

Antibodies against SARAF are crucial tools for investigating calcium signaling pathways, particularly in contexts where dysregulated calcium homeostasis contributes to pathological conditions such as cancer, neurological disorders, and vascular diseases. Recent studies indicate SARAF plays important roles in endothelial cell activation, angiogenesis, and breast cancer progression .

What are the key considerations when selecting a SARAF antibody?

When selecting a SARAF antibody, researchers should consider:

• Antibody format: Commercial SARAF antibodies are available in various formats including polyclonal, monoclonal, and conjugated variants (e.g., FITC-conjugated)

• Host species: Most common are rabbit-derived, which influences secondary antibody selection

• Epitope region: Some antibodies target specific regions, such as the middle region or the 277-327 amino acid region

• Validated applications: Confirm the antibody has been validated for your specific application (WB, IF, IHC, ELISA)

• Species reactivity: Many SARAF antibodies react with human, mouse, and rat proteins, but cross-reactivity varies by product

What methods are recommended for validating SARAF antibodies?

Proper antibody validation is essential before experimental use. Recommended validation methods include:

• Western blotting: Verify a single band at the expected molecular weight (37 kDa for human SARAF)

• siRNA knockdown control: Compare antibody signal in cells transfected with SARAF siRNA versus scramble control

• Immunofluorescence: Confirm endoplasmic reticulum membrane localization pattern

• Positive control samples: Test in tissues/cells known to express SARAF (e.g., endothelial cells)

• Negative controls: Primary antibody omission controls for immunofluorescence

In published studies, researchers have successfully used dilutions ranging from 1:200 to 1:1000 for Western blotting and 1:200 for immunofluorescence .

How can researchers effectively detect SARAF-Orai1 protein interactions?

Multiple methods have been validated for detecting SARAF-Orai1 interactions:

• Co-immunoprecipitation (Co-IP):

  • Immunoprecipitate with anti-SARAF antibody and probe with anti-Orai1 antibody in Western blotting

  • Typical lysis conditions: Nonidet P-40 buffer (274 mM NaCl, 40 mM Tris, 4 mM EDTA, 20% glycerol, 2% Nonidet P-40, 2 mM Na₃VO₄, and protease inhibitors)

  • For optimal results, use 2 μg of anti-SARAF antibody with 25 μl of protein A-agarose

• Proximity Ligation Assay (PLA):

  • Direct visualization of SARAF-Orai1 proximity (<40 nm)

  • Researchers detected 644 red puncta in 165 cells when using specific primary antibodies against SARAF and Orai1

  • Include proper controls (single antibody controls showed no PLA signal)

• Immunofluorescence co-localization:

  • SARAF and Orai1 show uniform distribution in HUVECs with a Pearson's correlation coefficient (PCC) of approximately 0.46

![Figure: SARAF and Orai1 colocalization in HUVECs showing fluorescence images with SARAF (green), Orai1 (red), and nuclei (blue). Merge image shows colocalization indicated by yellow color.]

What techniques are most effective for studying SARAF's role in calcium regulation?

Several specialized techniques have proven effective:

• Calcium imaging using Fura-2:

  • Allows measurement of intracellular Ca²⁺ changes in SARAF-manipulated cells

  • SARAF knockdown significantly enhances SOCE in T47D cells while suppressing it in MDA-MB-468 cells

• SARAF gene silencing through siRNA:

  • Transfection with siRNA against SARAF impacts:

    • Tube formation (40% reduction in mesh-like structures compared to scramble control)

    • Cell proliferation (40% reduction in Ki67-positive cells)

    • Cell migration (impaired wound closure in wound-healing assays)

• Jasplakinolide-based interaction analysis:

  • This specialized technique uses jasplakinolide (10 μM for 30 min at 37°C) to induce polymerization and stabilization of actin filaments at the cell periphery

  • Creates a cortical actin barrier that prevents interaction between intracellular organelles and the plasma membrane

  • Allows differentiation between ER-resident SARAF interactions and plasma membrane SARAF interactions

How does SARAF expression differ between healthy tissues and disease states?

Research has revealed complex patterns of differential SARAF expression:

• Breast cancer subtypes:

  • SARAF functions differently in ER+ versus triple-negative breast cancer (TNBC) cells

  • SARAF knockdown enhances SOCE in ER+ cells (T47D) but suppresses it in TNBC cells (MDA-MB-468)

• Multiple sclerosis:

  • Cholecalciferol supplementation induces up-regulation of SARAF gene expression

  • Higher dose (4000 IU) produced statistically significant up-regulation (p = 0.046) compared to lower dose (1000 IU, p = 0.256)

  • Some studies suggest SARAF may be preferentially expressed in multiple sclerosis patients, though findings show discrepancies between populations

• Neuroblastoma cells:

  • SARAF overexpression attenuates cell survival of SH-SY5Y cells stimulated with all-trans retinoic acid (ATRA)

  • The effect appears mediated through the PLA2/AA pathway, suggesting that impairment of AA-evoked Ca²⁺ signals by SARAF attenuates cell survival roles

What are the recommended protocols for immunofluorescence staining of SARAF?

Based on successful published protocols:

• Cell fixation and permeabilization:

  • Fix cells with 4% paraformaldehyde (15 minutes at room temperature)

  • Permeabilize with blocking buffer containing 0.3% Triton X-100

• Blocking and antibody incubation:

  • Block with 0.1 M Tris-HCl (pH 7.5), 0.15 M NaCl, 0.5% blocking reagent, and 0.3% Triton X-100

  • Primary antibody: Anti-SARAF (1:200; e.g., Cat. No. PA5-24237, Thermo Fisher Scientific)

  • Secondary antibody: Goat anti-rabbit Alexa Fluor 488

• Mounting and visualization:

  • Mount using fluorescence mounting medium (e.g., Dako)

  • Optimal visualization at 40× objective with 2× zoom

What controls should be included when using SARAF antibodies in experimental setups?

Include these essential controls:

• Antibody specificity controls:

  • Negative control: Primary antibody omission

  • Isotype control: Using matched isotype IgG at the same concentration

• Expression validation controls:

  • Positive control: Tissues/cells known to express SARAF

  • SARAF knockdown: Cells treated with SARAF siRNA

  • SARAF overexpression: Cells transfected with SARAF expression vector

• For co-localization studies:

  • Single-staining controls to rule out bleed-through

  • PLA controls with only one primary antibody (should show no signal)

• For functional studies:

  • Scramble siRNA control alongside SARAF siRNA

  • Empty vector control alongside SARAF overexpression vector

How can SARAF gene expression be accurately quantified in experimental samples?

Established protocols for SARAF expression analysis include:

• RNA extraction and RT-qPCR:

  • Extract RNA using miRNeasy kit (Qiagen)

  • Reverse transcribe using iScript Advanced cDNA Synthesis Kit (Bio-Rad)

  • Perform qPCR with iTaq Universal SYBR Green Supermix

  • Recommended reference gene: 18S rRNA

• Western blot analysis:

  • Use rabbit polyclonal anti-SARAF antibodies (1:1000 dilution)

  • Expected molecular weight: 37 kDa

  • Recommended loading control: β-actin or GAPDH

• Data normalization and analysis:

  • For Western blot: Density measurement using chemiluminescent scanners

  • For RT-qPCR: Use the comparative Ct method (2^-ΔΔCt)

  • Statistical analysis typically employs one-way ANOVA with Fisher's LSD test for multiple comparisons

How is SARAF implicated in cancer research, and what methodologies are used to study this connection?

SARAF's role in cancer involves several mechanisms:

• Differential function in breast cancer subtypes:

  • In ER+ breast cancer cells: SARAF acts as a negative regulator of SOCE

  • In TNBC cells: SARAF functions as a positive regulator of SOCE

  • These effects were demonstrated through calcium imaging following SARAF knockdown

• Cell survival in neuroblastoma:

  • SARAF overexpression attenuates retinoic acid-induced cell survival in SH-SY5Y cells

  • Apoptosis assays show increased percentage of apoptotic cells with SARAF overexpression, similar to PLA2 inhibition with AACOCF3

• Methodological approaches:

  • Gene silencing using siRNA transfection

  • Calcium imaging with fluorescent indicators (Fura-2)

  • Cell viability and apoptosis assays

  • Co-immunoprecipitation to identify protein interactions

What role does SARAF play in neurological and autoimmune disorders?

Emerging research reveals complex roles:

• Multiple sclerosis:

  • Cholecalciferol supplementation induces SARAF up-regulation

  • The proposed mechanism involves a negative feedback loop between SARAF and miR-155-5p expression

  • High-dose supplementation (4000 IU) showed statistically significant SARAF up-regulation (p = 0.046)

• Calcium regulation in immune function:

  • SARAF is required for proper T-cell-evoked transcription

  • It fine-tunes intracellular Ca²⁺ responses and subsequent downstream gene expression in immune cells

• Research approaches:

  • RT-qPCR for gene expression analysis

  • Genotyping to identify variant associations

  • eQTL analyses to reveal correlations between miRNAs and SARAF gene

How can researchers effectively design experiments to study SARAF in angiogenesis?

Based on published methodologies:

• In vitro angiogenesis models:

  • Tube formation assay: Seed HUVECs on Matrigel and quantify mesh-like structures

  • Cell migration: Wound-healing assay measuring wound closure over 24 hours

  • Proliferation: Ki67 nuclear staining in HUVECs cultured with growth factors

• Ex vivo models:

  • Rat aorta ring assay using Matrigel matrix

  • Visualization of live cells using Calcein-AM

• Gene manipulation approaches:

  • siRNA knockdown of SARAF (verified by qRT-PCR)

  • Comparison with Orai1 knockdown and scramble control

  • Quantification methods: mesh formation (reduced by ~40% with SARAF silencing), Ki67-positive nuclei (reduced by ~40%), wound closure rate